Skip to Main Content

Advertisement

Umbrella Alt Text
header search
Search
Advanced Search
Skip Nav Destination

Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor

Cancer Discov (2019) 9 (7): 926–943.
This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.
Comprehensive mutational scanning of EGFR reveals TKI sensitivities of extracellular domain mutants
  • Tikvah K. Hayes
  • Elisa Aquilanti
  • Nicole S. Persky
  • Xiaoping Yang
  • Erica E. Kim
  • Lisa Brenan
  • Amy B. Goodale
  • Douglas Alan
  • Ted Sharpe
  • Robert E. Shue
  • Lindsay Westlake
  • Lior Golomb
  • Brianna R. Silverman
  • Myshal D. Morris
  • Ty Running Fisher
  • Eden Beyene
  • Yvonne Y. Li
  • Andrew D. Cherniack
  • Federica Piccioni
  • J. Kevin Hicks
  • Andrew S. Chi
  • Daniel P. Cahill
  • Jorg Dietrich
  • Tracy T. Batchelor
  • David E. Root
  • Cory M. Johannessen
  • Matthew Meyerson
Nature Communications (2024) 15 (1)
Liquid biopsy for the management of NSCLC patients under osimertinib treatment
  • Aliki Ntzifa
  • Theodoros Marras
  • Vasilis Georgoulias
  • Evi Lianidou
Critical Reviews in Clinical Laboratory Sciences (2024) 61 (5): 347.
Linking ATP and allosteric sites to achieve superadditive binding with bivalent EGFR kinase inhibitors
  • Florian Wittlinger
  • Blessing C. Ogboo
  • Ekaterina Shevchenko
  • Tahereh Damghani
  • Calvin D. Pham
  • Ilse K. Schaeffner
  • Brandon T. Oligny
  • Surbhi P. Chitnis
  • Tyler S. Beyett
  • Alexander Rasch
  • Brian Buckley
  • Daniel A. Urul
  • Tatiana Shaurova
  • Earl W. May
  • Erik M. Schaefer
  • Michael J. Eck
  • Pamela A. Hershberger
  • Antti Poso
  • Stefan A. Laufer
  • David E. Heppner
Communications Chemistry (2024) 7 (1)
Targeting the EGFR/RAS/RAF signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020–2023)
  • Rima Hajjo
  • Dima A. Sabbah
  • Sanaa K. Bardaweel
  • Haizhen A. Zhong
Expert Opinion on Therapeutic Patents (2024) 34 (1-2): 51.
Discovery of new cyclopropane sulfonamide derivatives as EGFR inhibitors to overcome C797S-mediated resistance and EGFR double mutation
  • Han Yao
  • Yuanyuan Ren
  • Feng Wu
  • Jiadai Liu
  • Jianheng Li
  • Longcai Cao
  • Ming Yan
  • Xingshu Li
European Journal of Medicinal Chemistry (2024) 275: 116590.
A Constitutive EGFR Kinase Dimer to Study Inhibitor Pharmacology
  • Justin J. Kim
  • Ilse K. Schaeffner
  • David E. Heppner
  • Ciric To
  • Pasi A. Jänne
  • Tyler S. Beyett
  • Michael J. Eck
Molecular Pharmacology (2024) 105 (2): 97.
Structural Analysis of the Macrocyclic Inhibitor BI‐4020 Binding to EGFR Kinase
  • Tyler S. Beyett
  • Jaimin K. Rana
  • Ilse K. Schaeffner
  • David E. Heppner
  • Michael J. Eck
ChemMedChem (2024) 19 (12)
Targeting Solvent-Front Mutations for Kinase Drug Discovery: From Structural Basis to Design Strategies
  • Yang Zhou
  • Jibo Kang
  • Xiaoyun Lu
Journal of Medicinal Chemistry (2024) 67 (17): 14702.
Oncogenic alterations in advanced NSCLC: a molecular super-highway
  • Alex Friedlaender
  • Maurice Perol
  • Giuseppe Luigi Banna
  • Kaushal Parikh
  • Alfredo Addeo
Biomarker Research (2024) 12 (1)
ZNL0325, a Pyrazolopyrimidine-Based Covalent Probe, Demonstrates an Alternative Binding Mode for Kinases
  • Zhengnian Li
  • Wenchao Lu
  • Tyler S. Beyett
  • Scott B. Ficarro
  • Jie Jiang
  • Jason Tse
  • Audrey Yong-Ju Kim
  • Jarrod A. Marto
  • Jianwei Che
  • Pasi A. Jänne
  • Michael J. Eck
  • Tinghu Zhang
  • Nathanael S. Gray
Journal of Medicinal Chemistry (2024) 67 (4): 2837.
Novel EGFR inhibitors against resistant L858R/T790M/C797S mutant for intervention of non-small cell lung cancer
  • Xiaoxue Wang
  • Zhongxiang Qin
  • Wenrui Qiu
  • Kejia Xu
  • Yuting Bai
  • Beilei Zeng
  • Yakun Ma
  • Shuang Yang
  • Yi Shi
  • Yan Fan
European Journal of Medicinal Chemistry (2024) 277: 116711.
The Role and Future Development of EGFR Allosteric Inhibitors in the Treatment of Small Cell Lung Cancer
  • 硕磊 贾
Hans Journal of Medicinal Chemistry (2024) 12 (03): 185.
A macrocyclic kinase inhibitor overcomes triple resistant mutations in EGFR-positive lung cancer
  • Mai Suzuki
  • Ken Uchibori
  • Tomoko Oh-hara
  • Yumi Nomura
  • Ryusei Suzuki
  • Ai Takemoto
  • Mitsugu Araki
  • Shigeyuki Matsumoto
  • Yukari Sagae
  • Mutsuko Kukimoto-Niino
  • Yusuke Kawase
  • Mikako Shirouzu
  • Yasushi Okuno
  • Makoto Nishio
  • Naoya Fujita
  • Ryohei Katayama
npj Precision Oncology (2024) 8 (1)
Chemical Scaffolds for the Clinical Development of Mutant-Selective and Reversible Fourth-Generation EGFR-TKIs in NSCLC
  • Emiliano Laudadio
  • Luca Mangano
  • Cristina Minnelli
ACS Chemical Biology (2024) 19 (4): 839.
Icotinib in a lung adenocarcinoma patient with acquired EGFR 19del/C797S mutation-mediated resistance to osimertinib: a case report
  • Fei Cai
  • Yuanyuan Zhao
  • Shuxi Song
  • Dong Zhao
  • Zhendong Zheng
  • Long Xu
Anti-Cancer Drugs (2024) 35 (8): 764.
Next-generation EGFR tyrosine kinase inhibitors to overcome C797S mutation in non-small cell lung cancer (2019–2024)
  • Debasis Das
  • Lingzhi Xie
  • Jian Hong
RSC Medicinal Chemistry (2024) 15 (10): 3371.
Discovery of a potent, selective, and orally available EGFR C797S mutant inhibitor (DS06652923) with in vivo antitumor activity
  • Hideaki Kageji
  • Takayuki Momose
  • Masayuki Ebisawa
  • Yusuke Nakazawa
  • Hiroyuki Okada
  • Noriko Togashi
  • Yasuhito Nagamoto
  • Wataru Obuchi
  • Isao Yasumatsu
  • Kawori Kihara
  • Kumiko Hiramoto
  • Megumi Minami
  • Naomi Kasanuki
  • Takeshi Isoyama
  • Hiroyuki Naito
  • Naoki Tanaka
Bioorganic & Medicinal Chemistry (2024) 111: 117862.
Design, synthesis, and biological evaluation of diphenyl ether substituted quinazolin-4-amine derivatives as potent EGFRL858R/T790M/C797S inhibitors
  • Dou Dou
  • Xingsen Zhang
  • Jie Wang
  • Gulinuer Wumaier
  • Yunjin Qiao
  • Lijuan Xie
  • Wenzhe Jiang
  • Wenjie Sha
  • Wenjie Li
  • Wenyi Mei
  • Chen Zhang
  • Huan He
  • Caolin Wang
  • Lingkang Wu
  • Yanyan Diao
  • Lili Zhu
  • Zhenjiang Zhao
  • Zhuo Chen
  • Yufang Xu
  • Shengqing Li
  • Honglin Li
European Journal of Medicinal Chemistry (2024) 279: 116858.
Discovery of a Novel Potent EGFR Inhibitor Against EGFR Activating Mutations and On-Target Resistance in NSCLC
  • Eun Ji Lee
  • Seung Yeon Oh
  • You Won Lee
  • Ju Young Kim
  • Min-Je Kim
  • Tae Ho Kim
  • Jii Bum Lee
  • Min Hee Hong
  • Sun Min Lim
  • Anke Baum
  • Lydia Woelflingseder
  • Harald Engelhardt
  • Mark Petronczki
  • Flavio Solca
  • Mi Ran Yun
  • Byoung Chul Cho
Clinical Cancer Research (2024) 30 (8): 1582.
Design, Synthesis, and Biological Evaluation of Novel Diaminopyrimidine Macrocycles as Fourth Generation Reversible EGFR Inhibitors That Overcome Clinical Resistance to Osimertinib Mediated by C797S Mutation
  • Shiliang Hu
  • Linjiang Tong
  • Qiao Qin
  • Jiaxin Wen
  • Yan Li
  • Fang Feng
  • Kunzhong Wu
  • Yang Zhou
  • Jinsai Shang
  • Junjian Wang
  • Jinbao Liu
  • Hua Xie
  • Xiaoyun Lu
Journal of Medicinal Chemistry (2024) 67 (22): 20531.
Molecular Bidents with Two Electrophilic Warheads as a New Pharmacological Modality
  • Zhengnian Li
  • Jie Jiang
  • Scott B. Ficarro
  • Tyler S. Beyett
  • Ciric To
  • Isidoro Tavares
  • Yingde Zhu
  • Jiaqi Li
  • Michael J. Eck
  • Pasi A. Jänne
  • Jarrod A. Marto
  • Tinghu Zhang
  • Jianwei Che
  • Nathanael S. Gray
ACS Central Science (2024) 10 (6): 1156.
Osimertinib in Early-Stage EGFR-Mutated Non-small Cell Lung Cancer: A Narrative Review of Its Impact on Survival, Safety, and Clinical Outcomes
  • Mohammed Khaleel Almadhoun
  • Salsapil Faris
  • Naeel Al-Far
  • Abdrhman Al-Hmarat
Cureus (2024)
Exploring acenocoumarol and silodosin as allosteric EGFR inhibitors for the treatment of non-small cell lung cancer
  • Swastika Maity
  • Krishnaprasad Baby
  • Bharath Harohalli Byregowda
  • Megh Pravin Vithalkar
  • Usha Y Nayak
  • K Sreedhara Ranganath Pai
  • Yogendra Nayak
F1000Research (2024) 13: 1398.
Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges
  • Yuchu Xiang
  • Xudong Liu
  • Yifan Wang
  • Dawei Zheng
  • Qiuxing Meng
  • Lingling Jiang
  • Sha Yang
  • Sijia Zhang
  • Xin Zhang
  • Yan Liu
  • Bo Wang
Frontiers in Immunology (2024) 15
Identification of novel aminopyrimidine derivatives for the treatment of mutant NSCLC
  • Liping Hu
  • Shengmin Shi
  • Xiaomeng Song
  • Fangli Ma
  • Oulian Ji
  • Baohui Qi
European Journal of Medicinal Chemistry (2024) 265: 116074.
Tyrosine kinase inhibitors in cancers: Treatment optimization – Part I
  • David Combarel
  • Léa Dousset
  • Stéphane Bouchet
  • Florent Ferrer
  • Pauline Tetu
  • Céleste Lebbe
  • Joseph Ciccolini
  • Nicolas Meyer
  • Angelo Paci
Critical Reviews in Oncology/Hematology (2024) 199: 104384.
Insights into the Overcoming EGFRDel19/T790M/C797S Mutation: A Perspective on the 2‐Aryl‐4‐aminothienopyrimidine Backbone
  • Xuan Zhang
  • Jie He
  • Shidi Xu
  • Li Fu
  • Pengwu Zheng
  • Shan Xu
  • Qingshan Pan
  • Wufu Zhu
ChemMedChem (2024) 19 (9)
Design, synthesis and biological evaluation of 2-phenylaminopyrimidine derivatives as EGFR inhibitors
  • Chunlei Tang
  • Jie Wang
  • Dong Wang
  • Huabing Wang
  • Shengkai Cui
  • Tianxin Xiao
  • Weizheng Fan
  • Yan Zhang
Bioorganic & Medicinal Chemistry Letters (2024) 101: 129648.
The value of protein allostery in rational anticancer drug design: an update
  • Ruth Nussinov
  • Hyunbum Jang
Expert Opinion on Drug Discovery (2024) 19 (9): 1071.
Quercetin Promotes Apoptosis of Gastric Cancer Cells through the EGFR-ERK Signaling Pathway
  • Yali Liu
  • Yan Li
  • Yanjun Jiang
  • Xin Zheng
  • Tianming Wang
  • Jing Li
  • Biyun Zhang
  • Jiarui Zhu
  • Xintong Wei
  • Ruihua Huang
  • Yong Zhang
  • Qiaoying Jin
  • Ignazio Restivo
Journal of Food Biochemistry (2024) 2024: 1.
The study of primary and acquired resistance to first-line osimertinib to improve the outcome of EGFR-mutated advanced Non-small cell lung cancer patients: the challenge is open for new therapeutic strategies
  • Alessandra Ferro
  • Gian Marco Marinato
  • Cristiana Mulargiu
  • Monica Marino
  • Giulia Pasello
  • Valentina Guarneri
  • Laura Bonanno
Critical Reviews in Oncology/Hematology (2024) 196: 104295.
Recent Applications of In Silico Approaches for Studying Receptor Mutations Associated with Human Pathologies
  • Matteo Pappalardo
  • Federica Maria Sipala
  • Milena Cristina Nicolosi
  • Salvatore Guccione
  • Simone Ronsisvalle
Molecules (2024) 29 (22): 5349.
Rationally designed BCR-ABL kinase inhibitors for improved leukemia treatment via covalent and pro-/dual-drug targeting strategies
  • Jie Sun
  • Liang Lou
  • Chengjun Zhu
  • Peng Chen
  • Guanghui Tang
  • Mingxi Gu
  • Shu Xia
  • Xiao Dong
  • Zhi-Min Zhang
  • Liqian Gao
  • Shao Q. Yao
  • Qicai Xiao
Journal of Advanced Research (2024)
Structure-based virtual screening and molecular dynamics simulations for detecting novel candidates for allosteric inhibition of EGFRT790M
  • Güneş Çoban
Journal of Biomolecular Structure and Dynamics (2024) 42 (2): 571.
Design, synthesis and biological evaluation of structurally new 4-indolyl quinazoline derivatives as highly potent, selective and orally bioavailable EGFR inhibitors
  • Pengxing He
  • Linna Du
  • Qingqing Dai
  • Guobo Li
  • Bin Yu
  • Linlin Chang
Bioorganic Chemistry (2024) 142: 106970.
BPI-28592 as a novel second generation inhibitor for NTRK fusion tumors
  • Jin Sheng
  • Hong Chen
  • Bang Fu
  • Hongming Pan
  • Jiabing Wang
  • Weidong Han
npj Precision Oncology (2024) 8 (1)
Advancements in fourth-generation EGFR TKIs in EGFR-mutant NSCLC: Bridging biological insights and therapeutic development
  • Carla Corvaja
  • Antonio Passaro
  • Ilaria Attili
  • Pamela Trillo Aliaga
  • Gianluca Spitaleri
  • Ester Del Signore
  • Filippo de Marinis
Cancer Treatment Reviews (2024) 130: 102824.
Novel bioactive 2‐phenyl‐4‐aminopyrimidine derivatives as EGFRDel19/T790M/C797S inhibitors for the treatment of non‐small cell lung cancer
  • Shidi Xu
  • Zhihui Zhou
  • Jie He
  • Jiaojiao Guo
  • Xiaoling Huang
  • Yufeng An
  • Qingshan Pan
  • Shan Xu
  • Wufu Zhu
Archiv der Pharmazie (2024) 357 (2)
Gaining Insights into Key Structural Hotspots within the Allosteric Binding Pockets of Protein Kinases
  • Swapnil P. Bhujbal
  • Joonhong Jun
  • Haebeen Park
  • Jihyun Moon
  • Kyungbae Min
  • Jung-Mi Hah
International Journal of Molecular Sciences (2024) 25 (9): 4725.
Targeting EGFR with molecular degraders as a promising strategy to overcome resistance to EGFR inhibitors
  • Qiangfeng Wang
  • Yumeng Zhu
  • Junping Pei
Future Medicinal Chemistry (2024) 16 (18): 1923.
A Review of the Molecular Determinants of Therapeutic Response in Non-Small Cell Lung Cancer Brain Metastases
  • Catherine Boldig
  • Kimberly Boldig
  • Sepideh Mokhtari
  • Arnold B. Etame
International Journal of Molecular Sciences (2024) 25 (13): 6961.
The great need to overcome osimertinib resistance in advanced non-small cell lung cancer: from combination strategies to fourth-generation tyrosine kinase inhibitors
  • Giuseppe Bronte
  • Alessia Belloni
  • Luana Calabrò
  • Lucio Crinò
Frontiers in Oncology (2024) 13
Research Advances of Small Molecule EGFR-TKIs in NSCLC
  • 亚南 胡
Pharmacy Information (2024) 13 (01): 1.
The multiple-action allosteric inhibition of TYK2 by deucravacitinib: Insights from computational simulations
  • Yiqiong Bao
  • Ran Xu
  • Jingjing Guo
Computational Biology and Chemistry (2024) 113: 108224.
Synthesis, In Silico Prediction, and In Vitro Evaluation of Anti-tumor Activities of Novel 4'-Hydroxybiphenyl-4-carboxylic Acid Derivatives as EGFR Allosteric Site Inhibitors
  • Wurood A. Shihab
  • Ammar A. Razzak Kubba
  • Lubna H. Tahtamouni
  • Khaled M. Saleh
  • Mai F. AlSakhen
  • Sana I. Kanaan
  • Abdulrahman M. Saleh
  • Salem R. Yasin
Current Medicinal Chemistry (2024) 31 (38): 6336.
Targeting EGFR degradation by autophagosome degraders
  • ZhongFeng Zhu
  • Jiaying Li
  • Shujun Shen
  • Hawaa Al-furas
  • Shengrong Li
  • Yichen Tong
  • Yi Li
  • Yucheng Zeng
  • Qianyi Feng
  • Kaiyue Chen
  • Nan Ma
  • Fengtao Zhou
  • Zhang Zhang
  • Zhengqiu Li
  • Jiyan Pang
  • Ke Ding
  • Fang Xu
European Journal of Medicinal Chemistry (2024) 270: 116345.
Non-small cell lung cancer: an update on emerging EGFR-targeted therapies
  • Valentina Favorito
  • Ilaria Ricciotti
  • Andrea De Giglio
  • Laura Fabbri
  • Renata Seminerio
  • Alessandro Di Federico
  • Eleonora Gariazzo
  • Silvia Costabile
  • Giulio Metro
Expert Opinion on Emerging Drugs (2024) 29 (2): 139.
Synthesis, activity, and their relationships of 2,4-diaminonicotinamide derivatives as EGFR inhibitors targeting C797S mutation
  • Hideaki Kageji
  • Takayuki Momose
  • Yasuhito Nagamoto
  • Noriko Togashi
  • Isao Yasumatsu
  • Yosuke Nishikawa
  • Kawori Kihara
  • Kumiko Hiramoto
  • Megumi Minami
  • Naomi Kasanuki
  • Takeshi Isoyama
  • Hiroyuki Naito
Bioorganic & Medicinal Chemistry Letters (2024) 98: 129575.
4D-QSAR and MIA-QSAR Studies of Aminobenzimidazole Derivatives as Fourth-generation EGFR Inhibitors
  • Xuegong Jia
  • Chaochun Wei
  • Nana Tian
  • Hong Yan
  • Hongjun Wang
Medicinal Chemistry (2024) 20 (2): 140.
Inhibitory effect of 1,4,5,6-tetrahydroxy-7,8-diprenylxanthone against NSCLC with L858R/T790M/C797S mutant EGFR
  • Jing Wang
  • Yuna Wang
  • Shuanggou Zhang
  • Yana Qu
  • Ruohan Zhang
  • Xuanjun Wang
  • Jun Sheng
  • Peiyuan Sun
Scientific Reports (2024) 14 (1)
  • Online ISSN 2159-8290
  • Print ISSN 2159-8274

AACR Journals

 

 

  • Copyright © 2023 by the American Association for Cancer Research.
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.
Accept